The National Healthcare Security Administration (NHSA), Ministry of Finance, National Health Commission, and Chinese Center for Disease Control and Prevention have released a Notice on \u201cOptimizing Relevant Medical Insurance Policies for Treatment Expenses of Patients with Novel Coronavirus Infection after Implementation of \u2018Class B and Class B Management\u2019”. The guidelines outline management changes for COVID-19 medications following the recent downgrade of the condition to a Class B infectious disease.<\/p>\n\n\n\n
Reimbursement and Funding Mechanisms<\/strong>
The Notice indicates that in-patient hospitalization expenses under the COVID-19 infection diagnosis and treatment guidelines will first be reimbursed by provincial Basic Medical Insurance (BMI) schemes, Major Disease insurance, and Medical Assistance schemes. Individual co-pays will be subsidized by the government. Local governments will initially cover all expenses, with the central government subsidizing up to 60% of the actual expenses incurred.<\/p>\n\n\n\n